Lilly Reports Tirzepatide Sales of $5.34 Billion and Successful Phase 2 NASH Trial

On February 6, 2024, Eli Lilly and Company released its Q4 and full-year financial report for 2023. The revenue from new products launched after 2022 in Q4 was $2.49 billion, mainly driven by the growth of two products containing tirzepatide. Other growth primarily came from the CDK4/6 inhibitor Verzenio and the SGLT2 inhibitor Jardiance.

Mounjaro, the hypoglycemic version of tirzepatide, achieved annual sales of $5.163 billion, continuing its previous myth of rapid growth.

Zepbound, the weight-loss version of tirzepatide, was approved in November last year and went on sale on December 5th, generating $176 million in sales in less than a month.

Tirzepatide has also achieved significant breakthroughs in expanded indications, demonstrating excellent efficacy in Phase II clinical trials for NASH.

Summary

In 2023, Novo Nordisk's semaglutide generated $21.2 billion in sales, while liraglutide achieved $2.75 billion, totaling $24 billion. Eli Lilly's tirzepatide reached $5.34 billion in sales, and dulaglutide achieved $7.13 billion, amounting to $12.47 billion. The combined sales of four core GLP-1 products from the two companies totaled $36.5 billion, supporting Eli Lilly's market value of $670 billion and Novo Nordisk's market value of $520 billion.

Editor: Bai Ji

This article is a reprint from the PharmSnap website. All images and text are copyrighted by the original author. The purpose of the reprint is to convey more information and does not represent the views of this platform. If there are any issues regarding content, copyright, or other problems, please leave a message on this platform, and we will address it promptly.。